Standard Biotools Inc (LAB)
NASDAQ:LAB
Want to see LAB full AI Analyst Report?
LAB Stock Chart & Stats
$1.41
>-$0.01(-0.28%)
At close: 4:00 PM EST
$1.41
>-$0.01(-0.28%)
Day’s Range― - ―
52-Week Range$0.79 - $1.72
Previous CloseN/A
Volume335.74K
Average Volume (3M)3.15M
Market Cap
$331.19M
Enterprise Value$88.39M
Total Cash (Recent Filing)$455.18M
Total Debt (Recent Filing)$29.49M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Jul 30, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding390,368,130
10 Day Avg. Volume5,353,687
30 Day Avg. Volume3,145,883
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.15
Price to Sales (P/S)5.72
P/FCF Ratio-5.91
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit2.12
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$1.35Price Target Upside-4.26% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$82.50M
Bulls Say, Bears Say
Bulls Say
Divestiture Proceeds And M&A FundingDivestiture proceeds of about $350 million provide upfront cash that can be deployed to fund strategic acquisitions and support the company's core M&A strategy.
Path To Adjusted EBITDAManagement's expectation to reach positive adjusted EBITDA by the end of 2026 signals a clear path toward profitability if macro pressures ease.
Restructuring And Cost ReductionsAnnounced restructuring and $40 million of cost actions are expected to improve operating margins and bolster the profit and loss statement.
Bears Say
Academic Funding And Demand WeaknessOngoing weakness in academic funding and soft capital expenditure trends are pressuring instrument demand and core revenue.
Fewer Near-term Catalysts And Limited Deal VisibilityFewer near-term catalysts and limited clarity on the pipeline, timing, structure, and funding of potential acquisitions constrain upside for the stock.
Reduced Growth Outlook From Asset SaleSale of SomaLogic lowers the company's growth outlook and reduces visibility on potential revenue-driving catalysts.
Standard BioTools News
LAB FAQ
What was Standard Biotools Inc’s price range in the past 12 months?
Standard Biotools Inc lowest stock price was $0.79 and its highest was $1.72 in the past 12 months.
What is Standard Biotools Inc’s market cap?
Standard Biotools Inc’s market cap is $331.19M.
When is Standard Biotools Inc’s upcoming earnings report date?
Standard Biotools Inc’s upcoming earnings report date is Jul 30, 2026 which is in 43 days.
How were Standard Biotools Inc’s earnings last quarter?
Standard Biotools Inc released its earnings results on May 05, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.047 by $0.007.
Is Standard Biotools Inc overvalued?
According to Wall Street analysts Standard Biotools Inc’s price is currently Overvalued.
Does Standard Biotools Inc pay dividends?
Standard Biotools Inc does not currently pay dividends.
What is Standard Biotools Inc’s EPS estimate?
Standard Biotools Inc’s EPS estimate is -0.01.
How many shares outstanding does Standard Biotools Inc have?
Standard Biotools Inc has 390,368,130 shares outstanding.
What happened to Standard Biotools Inc’s price movement after its last earnings report?
Standard Biotools Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.047. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of Standard Biotools Inc?
Currently, no hedge funds are holding shares in LAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Standard BioTools Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.35 (-4.26% Downside)
$1.35 (-4.26% Downside)
Blogger Sentiment
Bearish
LAB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.23%
12-Months-Change
Fundamentals
Return on Equity
-20.80%
Trailing 12-Months
Asset Growth
10.27%
Trailing 12-Months
Company Description
Standard Biotools Inc
Standard BioTools Inc., established in 1999 and based in South San Francisco, California, is a key player in providing advanced scientific tools. Formerly known as Fluidigm Corporation until its name change in April 2022, the company designs, produces, and distributes a variety of instruments, specialized consumables, and support services. These offerings cater to biomedical researchers and scientists worldwide, including those in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, assisting them in the creation of new therapeutics. The company operates through two main divisions: Proteomics and Genomics. Within these areas, it supplies instruments, disposable products, software, and services that enable the identification and functional analysis of proteins and genes. Standard BioTools’ innovative product line includes several advanced platforms: The SomaScan platform allows for the simultaneous measurement of numerous proteins, yielding extensive insights into biological pathways and disease progression. The CyTOF technology platform utilizes metal-tagged antibodies with time-of-flight mass spectrometry to overcome signal interference and boost multiplexing capabilities. Hyperion is a spatial biology platform that facilitates a deeper comprehension of tissue architecture by preserving spatial context while conducting high-dimensional molecular and proteomic analyses. The Biomark X9 system transforms high-throughput genomics, specifically designed for quantitative polymerase chain reaction (qPCR) applications. These instruments and consumables are intended strictly for research purposes. Standard BioTools serves a broad spectrum of clients, including academic research institutions, centers for translational research and medicine, cancer centers, clinical research laboratories, and companies in the biopharmaceutical, biotechnology, and plant/animal research industries. Furthermore, the company has established licensing agreements with prominent organizations such as the California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.
LAB Stock 12 Month Forecast
Average Price Target
$1.35
▼(-4.26% Downside)
Technical Analysis
Ownership Overview
49.99% Insiders
7.52% Mutual Funds
5.59% Other Institutional Investors
28.69% Public Companies and
Individual Investors